.
MergerLinks Header Logo

New Deal


Announced

Completed

EQT and Goldman Sachs Asset Management completed the acquisition of Parexel from Pamplona for $8.5bn.

Financials

Edit Data
Transaction Value£6,165m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Cross Border

Majority

Friendly

Acquisition

Private Equity

Single Bidder

United States

Biotechnology

biopharmaceutical services

Private

Completed

Synopsis

Edit

EQT and Goldman Sachs Asset Management, an asset management unit of GS, completed the acquisition of Parexel, a global clinical research organization focused on the development and delivery of innovative new therapies to advance patient, from Pamplona, a specialist investment manager, for $8.5bn. "Our investment in Parexel reflects EQT’s thematic focus on the life sciences industry, as well as our commitment to partner with businesses that have a positive impact on society. We are excited to partner with Goldman Sachs for the next stage of Parexel’s journey, and to back Jamie, who prior to his role at Parexel had been a long-time senior advisor to EQT, as well as the rest of the Parexel team," Eric Liu, EQT Partner and Global Co-Head of Healthcare.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US